Amgen Beats Q1 Estimates and Advances Weight Loss Drug
Amgen reported Q1 earnings of $5.15 per share as sales rose 4%. The firm slightly raised its 2026 outlook and expanded trials for its obesity drug MariTide.
Xurve View
Insights:
Xurve View
AMGEN INC reported a 4% rise in first-quarter product sales as it expanded Phase 3 trials for its experimental weight-loss drug, MariTide. The United States-based biotech beat earnings expectations with an adjusted EPS of $5.15, exceeding the $4.76 estimate. The results shift investor focus toward the company's ability to challenge the dominant weight-loss market with a less frequent dosing schedule.
